Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care

Dr. Pierre Gholam discusses the implementation gap in liver cancer care, where patients often fail to receive recommended treatments despite tumor board evaluations. He suggests that dedicated navigators are essential to ensure care plans are executed.
Why it matters
Improving the transition from clinical recommendations to actual patient care is critical for optimizing outcomes in oncology.
In an interview with CancerNetwork® at The Liver Meeting® 2026, Pierre Gholam, MD, professor of medicine at Case Western Reserve University School of Medicine and director of the Multidisciplinary Hepatobiliary Tumor Board at University Hospitals Cleveland, discussed why patients evaluated by multidisciplinary tumor boards may not receive the recommended treatment for their liver cancer.
Gholam, who co-led a Meet-the-Expert session on next-generation multidisciplinary liver tumor boards for hepatobiliary malignancies at the meeting, noted that tumor board recommendations are nonbinding but that treating physicians rarely depart from them. Instead, he said, plans of care more often break down at implementation, when appointments with multiple providers and additional procedures such as imaging can fall through the cracks, leading to incomplete or delayed treatment. He described a dedicated tumor board navigator as the only sure way to carry out these plans efficiently.
Transcript:
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in